knowledge -WSS

knowledge

author：explore 2025-09-29 22:53:30 - browse：2

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： The painfully weak evidence on taking collagen to treat arthritis

knowledge

WSS

Risky weight loss products often used by teens globally, per study

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Travel bans should be based on evidence, not politics or fear

New menopause drug shows promise in relief for hot flashes

Risky weight loss products often used by teens globally, per study

New Medicare drug pricing powers could soon be upended in court

knowledge

knowledge

knowledge

In Memoriam: Notable people who died in 2023

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

In Memoriam: Notable people who died in 2023

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

How one medical school became remarkably diverse

Choosing scientific sides in the fight against Alzheimer's

At least 13 dead in Texas as scorching temps continue

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

explore

In venture capital firm's success, lessons for turning crisis into profit

Hospitals use virtual reality to design more inclusive rooms for kids

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Ohioans vote in high

New Medicare drug pricing powers could soon be upended in court

The SUPPORT Act is critical to fighting the opioid crisis

focus

knowledge

hotspot

entertainment